# Congressional stock trades in GNPX (Genprex, Inc. Common Stock)

Congressional stock trades in Genprex, Inc. Common Stock (GNPX) from House and Senate STOCK Act filings. See which members of Congress bought or sold, disclosed amounts, and filing dates.

- Industry: Pharmaceutical Preparations
- Last close: $3.45
- Price updated: Sep 21, 2026
- Total congressional trades: 4
- Politicians trading: 1
- Last traded: Feb 5, 2026
- Source: https://tryglasshouse.ai/companies/GNPX.md

## Trading History

- Page: 1 of 1
- Results: 4 of 4
- Pagination query parameter: `page`

## 1. Tim Moore

- Member: Republican, House
- Transaction: Buy, $1,001 - $15,000
- Dates: traded Feb 5, 2026, disclosed Feb 20, 2026
- Market context: $1.96 at trade, $3.45 current (+76.02%)
- Politician: https://tryglasshouse.ai/politicians/M001236.md
- Record: https://tryglasshouse.ai/trades/f852e976-0e8b-4635-ae7e-f648482844e1.md

## 2. Tim Moore

- Member: Republican, House
- Transaction: Buy, $1,001 - $15,000
- Dates: traded Dec 18, 2025, disclosed Jan 7, 2026
- Market context: $2.17 at trade, $3.45 current (+58.99%)
- Politician: https://tryglasshouse.ai/politicians/M001236.md
- Record: https://tryglasshouse.ai/trades/85ee3a49-9fdc-47fc-a04a-007678b7ac59.md

## 3. Tim Moore

- Member: Republican, House
- Transaction: Buy, $1,001 - $15,000
- Dates: traded Nov 7, 2025, disclosed Dec 2, 2025
- Market context: $4.21 at trade, $3.45 current (-18.05%)
- Politician: https://tryglasshouse.ai/politicians/M001236.md
- Record: https://tryglasshouse.ai/trades/07156b38-7d88-4849-9deb-31b047a03f13.md

## 4. Tim Moore

- Member: Republican, House
- Transaction: Buy, $15,001 - $50,000
- Dates: traded Oct 29, 2025, disclosed Nov 12, 2025
- Market context: $6.64 at trade, $3.45 current (-48.04%)
- Politician: https://tryglasshouse.ai/politicians/M001236.md
- Record: https://tryglasshouse.ai/trades/28d372c0-a07f-4d9f-a05e-4f6e519b94e2.md



## About Genprex, Inc. Common Stock

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

Prices and percentage changes are market context, not portfolio returns. This information is not financial advice.